Evidence map›Paper›PMID 34360002›Full record

ArticleCells2021

The FibromiR miR-214-3p Is Upregulated in Duchenne Muscular Dystrophy and Promotes Differentiation of Human Fibro-Adipogenic Muscle Progenitors.

Nicole Arrighi, Claudine Moratal, Grégoire Savary, Julien Fassy, Nicolas Nottet, Nicolas Pons, Noémie Clément, Sandy Fellah, Romain Larrue, Virginie Magnone and 7 more

Abstract read
In one paragraph

Article in Cells, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. PdgfrαGenes & diseases · 2025
    Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Thrown for a loop: fibro-adipogenic progenitors in skeletal muscle fibrosis.American journal of physiology. Cell physiology · 2023
    Review
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Nicole ArrighiFaculté de Médecine, CNRS, Inserm, iBV, Université Côte d'Azur, 06107 Nice, France.
Claudine MoratalFaculté de Médecine, CNRS, Inserm, iBV, Université Côte d'Azur, 06107 Nice, France.
Grégoire SavaryFHU-OncoAge, CNRS, IPMC, Université Côte d'Azur, 06560 Valbonne, France.
Julien FassyFHU-OncoAge, CNRS, IPMC, Université Côte d'Azur, 06560 Valbonne, France.
Nicolas NottetFHU-OncoAge, CNRS, IPMC, Université Côte d'Azur, 06560 Valbonne, France.
Nicolas PonsFHU-OncoAge, CNRS, IPMC, Université Côte d'Azur, 06560 Valbonne, France.
Noémie ClémentFaculté de Médecine, CNRS, Inserm, iBV, Université Côte d'Azur, 06107 Nice, France.
Sandy FellahCANTHER-Cancer Heterogeneity Plasticity and Resistance to Therapies, Institut Pasteur Lille, CNRS, Inserm, CHU Lille, Université de Lille, UMR9020-UMR-S 1277, 59000 Lille, France.
Romain LarrueCANTHER-Cancer Heterogeneity Plasticity and Resistance to Therapies, Institut Pasteur Lille, CNRS, Inserm, CHU Lille, Université de Lille, UMR9020-UMR-S 1277, 59000 Lille, France.
Virginie MagnoneFHU-OncoAge, CNRS, IPMC, Université Côte d'Azur, 06560 Valbonne, France.ORCID 0000-0002-0912-0266
Kevin LebrigandFHU-OncoAge, CNRS, IPMC, Université Côte d'Azur, 06560 Valbonne, France.
Nicolas PottierCANTHER-Cancer Heterogeneity Plasticity and Resistance to Therapies, Institut Pasteur Lille, CNRS, Inserm, CHU Lille, Université de Lille, UMR9020-UMR-S 1277, 59000 Lille, France.
Claude DechesneFaculté de Médecine, CNRS, Inserm, iBV, Université Côte d'Azur, 06107 Nice, France.
Georges VassauxFHU-OncoAge, CNRS, IPMC, Université Côte d'Azur, 06560 Valbonne, France.ORCID 0000-0002-1149-7716
Christian DaniFaculté de Médecine, CNRS, Inserm, iBV, Université Côte d'Azur, 06107 Nice, France.ORCID 0000-0003-3228-0230
Pascal PeraldiFaculté de Médecine, CNRS, Inserm, iBV, Université Côte d'Azur, 06107 Nice, France.
Bernard MariFHU-OncoAge, CNRS, IPMC, Université Côte d'Azur, 06560 Valbonne, France.ORCID 0000-0002-0422-9182

Funding

Agence Nationale de la Recherche ANR-PRCI-18-CE92-0009-01Association Française contre les Myopathies 17708
6 · The paper itself

Abstract

Fibrosis is a deleterious invasion of tissues associated with many pathological conditions, such as Duchenne muscular dystrophy (DMD) for which no cure is at present available for its prevention or its treatment. Fibro-adipogenic progenitors (FAPs) are resident cells in the human skeletal muscle and can differentiate into myofibroblasts, which represent the key cell population responsible for fibrosis. In this study, we delineated the pool of microRNAs (miRNAs) that are specifically modulated by TGFβ1 in FAPs versus myogenic progenitors (MPs) by a global miRNome analysis. A subset of candidates, including several "FibromiRs", was found differentially expressed between FAPs and MPs and was also deregulated in DMD versus healthy biopsies. Among them, the expression of the TGFβ1-induced miR-199a~214 cluster was strongly correlated with the fibrotic score in DMD biopsies. Loss-of-function experiments in FAPs indicated that a miR-214-3p inhibitor efficiently blocked expression of fibrogenic markers in both basal conditions and following TGFβ1 stimulation. We found that FGFR1 is a functional target of miR-214-3p, preventing the signaling of the anti-fibrotic FGF2 pathway during FAP fibrogenesis. Overall, our work demonstrates that the « FibromiR » miR-214-3p is a key activator of FAP fibrogenesis by modulating the FGF2/FGFR1/TGFβ axis, opening new avenues for the treatment of DMD.

Indexed as

AdipocytesAdipogenesisAdolescentAdultBase SequenceCell DifferentiationChildFemaleFibroblast Growth Factor 2FibrosisGene Expression ProfilingGene Expression RegulationHumansMaleMicroRNAsMiddle AgedFGFR1 protein, humanFibroblast Growth Factor 2MicroRNAsMIRN214 microRNA, humanReceptor, Fibroblast Growth Factor, Type 1TGFB1 protein, humanTransforming Growth Factor beta1Duchenne muscular dystrophy (DMD)FGFR1fibro-adipogenic progenitor (FAP)fibrosismicroRNA (miRNA)transforming growth factor beta (TGFβ)

Identifiers

PMID34360002
PMCPMC8303294

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.